Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 1/20 | 0.51 |
| ▸ | MDM4 | O15151 | 3/20 | 0.49 |
| ▸ | TP53 | P04637 | 3/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.43 |
| ▸ | CCKAR | P32238 | 2/20 | 0.43 |
| ▸ | CCKBR | P32239 | 2/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30917941 | 1.00 | ADAM17 (0.51) | ADAM17MDM4TP53MDM2L3MBTL1 | |
| SCHEMBL29353403 | 1.00 | ADAM17 (0.51) | ADAM17MDM4TP53MDM2L3MBTL1 | |
| SCHEMBL1000833 | 1.00 | ADAM17 (0.51) | ADAM17MDM4TP53MDM2L3MBTL1 | |
| SCHEMBL29364320 | 1.00 | ADAM17 (0.51) | ADAM17MDM4TP53MDM2L3MBTL1 | |
| SCHEMBL1709188 | 1.00 | ADAM17 (0.51) | ADAM17MDM4TP53MDM2L3MBTL1 | |
| SCHEMBL12052757 | 0.93 | L3MBTL1 (0.48) | ADAM17MDM4TP53MDM2L3MBTL1 | |
| SCHEMBL8104292 | 0.93 | L3MBTL1 (0.48) | ADAM17MDM4TP53MDM2L3MBTL1 | |
| SCHEMBL30231797 | 0.93 | ADAM17 (0.51) | ADAM17MDM4TP53MDM2L3MBTL1 | |
| SCHEMBL119657 | 0.92 | MDM4 (0.53) | MDM4TP53MDM2SLC17A5 | |
| SCHEMBL120776 | 0.92 | MDM4 (0.53) | MDM4TP53MDM2SLC17A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020252713-A1 | MODIFIED HYDROPHOBIC AUXILIARY MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF | 浙江智达药业有限公司 | 2020-12-24 | — | — | WO | claimed |
| US-12030888-B2 | Himastatin derivatives, and processes of preparation thereof, and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2024-07-09 | — | — | US | disclosed |
| WO-2020252713-A1 | MODIFIED HYDROPHOBIC AUXILIARY MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF | 浙江智达药业有限公司 | 2020-12-24 | — | — | WO | disclosed |
| US-20100210552-A1 | HUMAN GLUCAGON-LIKE PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-19 | — | — | US | disclosed |
| US-20070287670-A1 | HUMAN GLUCAGON-LIKE PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2007-12-13 | — | — | US | disclosed |
| US-7001887-B2 | Blood coagulation factor VIIa inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2006-02-21 | — | — | US | disclosed |
| US-20040087511-A1 | Peptide derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-05-06 | — | — | US | disclosed |
| EP-1364960-A1 | PEPTIDE DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-11-26 | — | — | EP | disclosed |
| US-6372883-B1 | FOR THERAPY AND PROPHYLAXIS OF INFECTIONS CAUSED BY HEPATITIS C, HEPATITIS G AND HUMAN GB VIRUSES | HOFFMANN-LA ROCHE INC. | 2002-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030888-B2 | Himastatin derivatives, and processes of preparation thereof, and uses thereof | PCSK9, HMGCR, PCSK7 | ADAM17 738/4885MDM4 2375/4885TP53 4587/4885 |
| US-20070287670-A1 | HUMAN GLUCAGON-LIKE PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | GLP1R, IAPP, GIPR | ADAM17 328/4885MDM4 4381/4885TP53 3992/4885 |
| US-20100210552-A1 | HUMAN GLUCAGON-LIKE PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | GLP1R, IAPP, GIPR | ADAM17 328/4885MDM4 4381/4885TP53 3992/4885 |
| US-20040087511-A1 | Peptide derivatives | F7, F13B, HABP2 | ADAM17 73/4885MDM4 4172/4885TP53 4428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.